Category: Health

Asian’s Godfather of Cord Blood, Professor Takahashi Tsuneo Joined the “Cryolife Cord Blood Bank” and “Hong Kong Medisun”

In May 2017, CRYOLIFE Cord Blood Bank (Hong Kong Medisun Medical Group members) formally appointed the Godfather of Cord Blood in Asia, Japanese regenerative medicine expert Professor Takahashi Tsuneo as the Chief Scientist. Professor Takahashi will lead all the cord blood stem cell research projects. Professor Takahashi has eras of experience in the field of regenerative medicine. In the past few decades, Professor Takahashi has established the standards of the Cryo-Cord Blood in Asia and lead a new prospective in the application and development of the cord blood industry.

It is well believes that by the joining of Professor Takahashi will convey a new development stage in the field of cord blood stem cells in Hong Kong. It will bring new opportunities for the expansion of Medisun Medical Group and the Cryolife Cord Blood Bank.

Professor Takahashi Tsuneo is committed to the field of regenerative medicine for more than 40 years (mainly in the field of stem cells and cord blood bank). Currently he serves as Chief Executive Officer of Japan LIFEBANK and Chief Scientist of Hong Kong Cryolife Cord Blood Bank (Cryolife is a members of the Medisun Group). Prof. Takashi Tsuneo graduated from the Hokkaido University in Sapporo, Japan with a Ph.D. degree. He became the scientist in the Red Cross of Bethesda, Maryland. He later worked at the Research center for Arthritis, Diabetes and Kidney diseases of the National Institutes of Health in Bethesda, Maryland. Professor Takahashi Tsuneo returned to Japan, became the Red Cross Hokkaido Blood Center’s Research Director in Sapporo. Professor Takahashi is not only a founding member of the International Cord Blood Bank Alliance (NETCORD), but also Director of the Tokyo Cord Blood Bank Cell Treatment Center at the University of Tokyo, Japan, and Director of Cellular Research and Development for research center for cell therapy in New York. Professor Takahashi is a Visiting Professor at a number of well-known institutions, including: Department of Cellular Processing, Institute of Medical Sciences, University of Tokyo, Head of Hematology, Tokyo University Hospital, Head of Embryonic Stem Cell Research, Faculty of Forensic Medicine, Kyoto University, Kobe University Institute of Medicine and Pathology, and Department of Medicine, Peking University, China.

Application of Cord Blood

Cord blood is originated in the fetus, and collected at the umbilical cord ligation when separated from the residual placenta. Nearly a decade of research and discovered that umbilical cord blood contain the human hematopoietic and the hematopoietic stem cells of the immune system. It can be used for hematopoietic stem cell transplantation, for the treatment of more than 80 kinds of diseases. Thus, the cord blood has become an important source of hematopoietic stem cells, especially for no directly related family members. The hematopoietic stem cells is a very important human biological for treatment of diseases.

Worldwide, cord blood has been used to treat various types of Leukemia, Aplastic Anemia, Lymphoma, Multiple Myeloma, Neuroblastoma, Mucopolysaccharide disease, Thalassemia, Bone Marrow Dysplasia syndrome, Primary Immunodeficiency Disease, Chronic Granuloma and other 80 kinds of diseases.

Clinical application case

* The world’s first cord blood transplantation: In 1988, a 5-year-old French boy, suffering from Cooley’s Anemia has been treated with the cord blood transplantation and with completely recovered.
* The world’s first autologous cord blood transplantation: In 1997, a 14-month-old Brazilian girl, with autologous cord blood successfully cured Neuroblastoma.
* The world’s first double dosages of cord blood transplantation: In 2000, the Institute of Hematology of the Peking University used the world’s first double dose of cord blood transplantation for the treatment of Acute Lymphoblastic Leukemia with good result. Now, the patient weight of 95 kg, is having a healthy life.
* Asia’s first autologous cord blood transplantation: In 2009, Beijing Children’s Hospital, a pediatric patient using his own cord blood for the treatment of Neuroblastoma. This is the first case of autologous cord blood treatment for pediatric case. The baby is treated and being fine after the transplantation.
* China treated a youngest and light weight baby: In 2009, Shanghai Dao Pei Hospital has successfully treated a 2 months old baby only weight – 5 kg, by using the cord blood transplantation treatment for Primary Immunodeficiency Disease.
* In China, the first mother received the son’s cord blood transplantation as treatment: In 2009, Chongqing Xinqiao Hospital, a female patient suffering from an Acute Non-Lymphocytic Leukemia was treated by using her son’s umbilical cord blood, together with his husband’s bone marrow for transplantation. She was discharged from the Intensive Care Unit after one month from the transplantation. This is the first case of mother using her child’s cord blood for transplantation.

Treatment prospects

Cell therapy has been a biological way for the treatment of a number of diseases in the 21st century. At the end of May 2014, the worldwide of related clinical research on the cord blood cell therapy, registered with the United States National Institutes of Health (NIH) reached a total of 928.

CRYOLIFE Cord Blood Bank – Hong Kong’s first private cord blood bank

CRYOLIFE Cord Blood Bank is the only one in Hong Kong with the most international professional certification, and is highly recommended by gynecologist, physicians and parents. CRYOLIFE was established in 1996 to create the first private cord blood storage program in Asia. Prior to the establishment of the cord blood bank in Japan, Singapore, mainland China, Taiwan and Malaysia. Cryolife upgrades the standards in the development and research in the laboratory equipment. It is the leader in Hong Kong and Asian in the cord blood industry. CRYOLIFE has been recognized by the American Association of Blood Banks (AABB) since 2007 as one of the world’s first recognized AABB-approved cord blood banks, and range the first 50 in the Cord Blood Bank’s list. Continuous assessment were done in 2009, 2011, 2013 and 2015 and has successfully passed the review, and gain the AABB certification until the end of 2017. The company is the only one in Hong Kong which has obtained a 10 consecutive years’ certification in the private cord blood bank. (In February 2017) Hong Kong Medisun Medical Group acquired 51% stake in CRYOLIFE Cord Blood Bank as its controlling shareholder.)

MEDISUN MEDICAL GROUP

Headquartered in Hong Kong, Headquartered in Hong Kong, the company is committed to investing in R & D and commercialization of global regenerative medicine products, as well as professional medical investment groups in top hospitals and treatment centers.

Medisun invests extensively in regenerative medicine and stem cell patented technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, neurological diseases, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical and the US Mayo Clinic, Harvard University Stem Cell Research Institute, Johns Hopkins School of Life Science Center launched a long-term cooperation program, co-investment in regenerative medicine and stem cell therapy technology. Medisun collaborates with them as the business owned holdings and holds global intellectual property rights.

The Medisun Regenerative Medical Center is located in Kowloon, Hong Kong , with 50,000 square feet of stem cell GMP production base, cancer treatment center and anti-aging center, bringing together European, Japanese, American and individual Chinese experts for rigorous professional development process by providing immune cell therapy and a variety of stem cell treatments. Medisun is also the Asian Center, a representative of the Mayo Clinic Asia service agencies. It provides Mayo remote consultation, the second diagnosis and treatment, so that Chinese patients can not enjoy the authority of the medical services. Mayo Clinic provides more than three thousand biomedical tests for the most predictable health protection for our customers’ health.

Medisun Regenerative Medicine Center (Mayo Asia Medical Service Center | Cancer Treatment Center | Anti-Aging Center)

Medisun Medical Laboratory (Hong Kong)

Source : http://www.medisun.hk/

The famous American virologist – HIV virus discoverer Robert Gallo joined Medisun Medical Groupedisun

Bringing the best cancer and AIDS treatment technologies to China

Robert Gallo, a famous American virologist, joined Medisun Medical Groupedisun

In February 2017, Medisun Medical Group officially announced the appointment of Robert Charles Gallo, a famous American virologist, as a member of the board of directors of the group.

 

Dr. Robert Charles Gallo

Dr. Gallo is a famous American virologist whose best-known contribution is the discovery of the first human retrovirus (HTLV1, and HTLV2). In 1983, HTLV3 was discovered, which was later called the HIV, a virus that causes AIDS. He also studied the cytokine leukocyte 2, and in 1986 studied the pathogen human rash type 6 virus in children with acute rash. In 1982 and 1984, he received the Lasker Basic Medical Research Award (known as the “Nobel Prize in the United States”), the Charles Mott Award (Tumor Prevention Contribution Award) in 1984, and the Dickson International Award in 1985, 1988. Received the National Science and Technology Outstanding Contribution Award from Japan. Dr. Gallo is currently the Director of the Institute of Human Virology (IHV) at the University of Maryland and the founder and chief scientist of the Global Virus Network (GVN). He has served in the National Cancer of the United States. The National Cancer Institute has served as the director of the Laboratory of Cancer Cell Biology for 30 years. Dr. Gallo proposed the theory that the tumor system is caused by viruses and gradually improved its academic structure and clinical research.

Mr. Terry L. Lierman, founder of the US FDA, joined Medisun

At the same time , Mr.Terry L. Lierman entered the board of Medisun. Mr. Lierman is the founder of Summit Global Ventures and the CEO of Health Ventures LLC.Mr. Lierman has served on the US Senate Appropriations Committee and served as Director of the Sub-Committee on Labor Health and Human Services (HHS) Grants. Mr. Lierman is also the founder of Research America and NIH (National Institutes of Health) / FDA (US Food and Drug Administration) Board of Directors, and serves as the majority leader and member of the House of Representatives. He began his career in the health field of the NIH (National Institutes of Health) in 1971, where he assisted with budget and policy development, grants and contracts. For the past four decades, he has combined entrepreneurs and political talent in a variety of businesses.From leadership positions in the US Senate Appropriations Committee, founding companies and non-profit organizations, to promote health care advocacy, to lead and serve as chairman of the Maryland Democratic Party.

Mr.Terry L.Lierman

Chairman Medisun Wang Xiaofeng joined the Board of Directors of the Institute of Human Virology and the International Virus Alliance

At the same time that two world-class companies joined Medisun, Mr. Wang Xiaofeng, Chairman of Medisun Medical Group, was also invited to the Institute of Human Virology (IHV) and the Global Virus Network (GVN) at the University of Maryland as a member of the board of directors. Mr. Wang is the founder and chairman of the Board of Directors of Medisun Medical Group living in Canada and the United States for ten years. He moved to Hong Kong in 1996. Mr. Wang has more than 20 years of experience in the global capital market and medical industry, including industries including Medisunne, internet, education and media. Mr. Wang is currently Chairman of Hong Kong-listed National Investment Fund (01227.HK) and Chairman of Beijing Financial Group.

Mr. Danny Wong

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as top hospitals and treatment centers.

Medisun invests extensively in the fields of regenerative Medisunne and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical has a long-term cooperation plan with the US-Australia Clinic, the Harvard University Stem Cell Institute, and the Johns Hopkins Medical School Life Science Center to jointly invest in regenerative Medisunne and stem cell therapy technology, with Medisun as a co-operative business. The Medisun holding entity and holds global intellectual property rights.

The Medisun Reproductive Medisunne Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. 3,300 biomedical tests provide the most predictable health protection for customers’ health, adding more than 300 new testing items each year.

MEDISUN REGENERATIVE MEDICAL CENTER | CANCER TREATMENT CENTER | ANTI-AGING CENTER

Medisun Medical Laboratory (Hong Kong)

Medisun Medical Laboratory (Hong Kong)

Medisun announced that he will join the Biden Cancer Lunar Plan

At the end of 2016, Medisun announced that he would join the “Cancer Moon Plan” initiated by former US Vice President Biden. The “Cancer Moon Plan” was proposed by former US President Obama in early 2016 and was initiated by former Vice President Biden. The goal is to shorten the work schedule for cancer-related prevention, diagnosis, treatment and care that was expected to be completed in 5 years. Aiming to achieve 20,000 cancer treatments worldwide by 60 programs by 2020.
Dr. Gallo and Mr. Lierman will lead Medisun’s clinical research implementation, medical technology and project selection, medical resource introduction, etc., and bring the best technology in the world to China, highlighting the inevitable trend of China’s participation in the world’s most advanced technology research and development. . At the same time, Medisun’s clinical research bases in Hong Kong, Beijing, Shanghai, Guangzhou and Tokyo will participate in the world’s most advanced clinical research.
Dr. Gallo and Mr. Lierman joined Medisun and Chairman Wang Xiaofeng to enter the IHV and GVN Board of Directors, indicating that Medisun will work with IHV and GVN to make valuable preparations for the cancer landing program and to fully participate in the global research and development of cancer treatment.

The Human Virology Institute (IHV) is the world’s first research center that combines basic science, epidemiology and clinical research disciplines to accelerate the diagnosis and treatment of chronic viruses and immune diseases (mostly HIV, AIDS the reason). IHV’s laboratory is a US key laboratory that receives more than $200 million in annual US research funding.
Founded in 1996 as a partner of the University of Maryland, IHV is a research institute at the University of Maryland School of Medisun, bringing together a globally recognized and world-renowned expert in human virology. The IHV was co-founded by Robert Gallo (Director of IHV) and William Blattner.MD. The IHV also includes the Animal Model Department, the Basic Science Department and the Vaccine Research Department.
The institute has a variety of laboratory and patient care facilities located in Baltimore, Maryland. IHV has created an environment of close collaboration between multidisciplinary research, education and clinical research and development, accelerating scientific understanding of the incidence of HIV/AIDS, and developing interventions to curing cancers of HIV and viruses possible.
IHV’s research focuses on how to use the body’s natural chemistry to its own therapeutic potential, and to discover biotherapeutics that are less toxic to the body and more economical for the public. IHV is also committed to developing effective therapeutic and preventive vaccines that are dedicated to ending the AIDS epidemic.
IHV has more than 300 employees, including 70 professors, whose research focuses on chronic human viral infections and diseases. Currently, more than 75% of the Institute’s clinical and research work addresses HIV infection, but also includes hepatitis C virus, human T-cell leukemia virus 1 and 2, human papillomavirus, herpes virus and cancer research. The patient base of IHV has grown from just 200 patients to about 6,000 in Baltimore, and nearly 1 million in 6 African and 1 Caribbean countries.

The Global Network of Viruses (GVN) is a global organization for the research of viral diseases. It is a consortium of authoritative virologists from more than 20 countries around the world. It is dedicated to the research, development of drugs and vaccines to prevent diseases and death. GVN is the only single organization in the world that has special research in all areas of the virus. GVN brings together the world’s best medical virology experts to focus on difficult scientific issues around the world. The strength of GVN lies in its global reach, the depth of science, and its vision to address the viral challenges facing humanity.

GVN achieves its goals through three strategic action platforms:

Support research

Public education

Advocate a statement supporting the global virus network

Established in Washington, DC, the organization supports the goals and ideals of a global virus network, actively trains younger generations of medical virologists, and provides advice to governments or NGOs on viral diseases to fill the current international health development important needs.

Source: http://www.medisun.hk/

Hong Kong National Investment and Harvard University Stem Cell Institute have a strong cooperation.

Mr. Brock Reeve, CEO of Harvard Stem Cell Research Institute, is the Chief Investment Officer of Stem Cell and Regenerative Medisun at National Investment and Medici Medical Group.

2015-05-11 China Securities Journal

On May 8, 2015, Hong Kong Medisun Regerative Medical Center and National Investment (01227.HK) announced the appointment of Mr. Brock Reeve as the chief stem cell and regenerative medicine investment officer of the two companies.

Mr. Brock Reeve is currently the Executive Director of the Harvard University Stem Cell Institute and has graduated from Yale University and Harvard Business School. Mr. Reeve is solely responsible for the strategy and operations of the Harvard Stem Cell Institute, whose overall goal is to use stem cell biology as a tool and treatment to study and treat major degenerative diseases.

As the Chief Investor of Stem Cell and Regenerative Medicine of Medisun Medical Center, Mr. Brock Reeve will organize and lead a professional investment team to actively select the latest regenerative medicine technologies in overseas markets such as Europe, the United States, and Japan and evaluate their investment value. They will also focus on and invest in the world’s leading stem cell regenerative medicine technology, and actively participate in clinical trials and product commercialization of stem cell technology invested by Medisun Medical Center in Asia.

Medisun Medical Center is the world’s most authoritative investment organization in stem cell and regenerative medicine

As the world’s most authoritative investment organization for stem cells and regenerative medicine, Medisun Medical Center has invested in stem cell treatment technologies including heart, tumor, liver, kidney, AIDS and other diseases, fully demonstrating its investment vision and courage. After working with the Mayo Medical Group in the United States, the Medisun once again joined forces with the Harvard University Stem Cell Institute.

Mr. Danny Wong is both the Chairman of the Medisun Medical Group and National Investment (01227.HK). He has devoted himself to research and investment in the field of stem cells for the past five years. The Medisun currently has more than 300 scientists , medical consultants and investment experts from all over the world. The technologies invested by the group are distributed in Europe, the United States, Japan, Hong Kong and other places, and clinical trials are carried out simultaneously.

China’s first participation in international multi-center global synchronized clinical trials

Medisun Medical Group is committed to bringing the world’s leading stem cell and regenerative medicine technologies to China. The investment in the C-cure stem cell therapy for ischemic heart failure technology, which was invented by Mayo Medical Group, has been clinically tested in Europe and the United States. It will carry out clinical trials in China’s well-known cardiovascular hospitals such as Beijing Anzhen Hospital, Fuwai Cardiovascular Hospital and Shanghai Oriental Hospital with the support of international multi-center policy, giving Chinese hospitals the opportunity to participate in the world’s most advanced stem cell technology clinic. The Medisun also actively promote the commercialization of technology worldwide in the future. Before C-Cure’s great technology and revolutionary products for heart disease were officially launched, Medisun has launched a series of cell regeneration factor products to treat a number of diseases, and the product has entered the market.

Liang Zhen ying visits Harvard University Stem Cell Research Institute and Mr. Brock Reeve to discuss the promotion of stem cell and the development of regenerative medicine industry

Under the general environment of Hong Kong’s adjustment of the whole industry, one of the important measures is to develop the stem cell and regenerative medicine industries. Looking at the huge investment in the stem cell and regeneration field of the Medisun Medical Group, it is revealed that it will inevitably set off a disruptive business model in the market.

The Hong Kong government attaches great importance to the development of stem cells. Following the cooperation with the Caroline Medical School in Sweden, Liang Zhen ying visited the Harvard University Stem Cell Research Institute on May 5 and exchanged views with its Executive Director Brock Reeve to promote the development of the stem cell industry in Hong Kong. This will undoubtedly inject a strong shot into the cooperation between Harvard University and Hong Kong in the field of regenerative medicine. It will promote the promotion of Harvard stem cells in regenerative medicine research and technology in Hong Kong and Asia.

It can be seen that Medisun Medical Group has appointed Mr. Brock Reeve take the helm of the stem cell and regenerative medicine to investment. National Investment (01227.HK), which holds a 30% stake in Medisun Medical Group, is investing in regenerative medicine and the field of stem cells. Mr. Brock Reeve will lead the Medisun Medical Group to become a professional stem cell investment team with global leadership.

The value of the stem cell and regenerative medicine industry under the capital market in China and Hong Kong is immeasurable.

With the upcoming clinical management of stem cells, the development of China’s stem cell and regenerative medicine industry will be unstoppable. Shanghai-Hong Kong Stock Connect and the upcoming Shenzhen-Hong Kong Stock Connect have apparently injected huge sums of money into Hong Kong stocks. The stocks of companies related to the stem cell industry have risen very well, but they are far from satisfactory and far from the technology held by Medisun Medical Center. National Investment (01227.HK), as a shareholder of Medisun Medical Group, is full of confidence in the development of the Group.

Medisun Investment Holdings’ Cardio Biotech plans to enter the US capital market.

Medisun Investment Holdings’ C-cure Stem Cell Therapy for Ischemic Heart Failure has exceeded the number of patients enrolled by the European Food and Drug Administration (EMA) in the Phase III clinical trial in Europe and has been approved by the US Food and Drug Administration (FDA). Enter the third phase of clinical. Cardio, the investment holding company of Medisun, also successfully obtained a new round of financing of 32 million euros in February this year. Its financing quota was oversubscribed and snapped up by European and American institutional investors. Cardio is planning to be listed on the NASDAQ in the United States from the end of May to the beginning of June this year (listed in Belgium and France in 2013), and the large-scale financing plan of Cardio further indicates that the spring of stem cells has really come.

After many years of favor and investment in the field of stem cells and regenerative medicine, and the huge capital investment plan, the Medisun’ next step will be the focus of the market. The capital market’s confidence in its shareholder, National Investment (01227.HK), is already evident in the expectation of its future development.According to analysts, Medisun has planned to launch an overall listing financing plan in Hong Kong in the near future. We believe that Medisun, as a recognized leader in the global stem cell and regenerative medicine field, will surely launch an incredible wave of development in this field.

The News Picture:

P1:

Mr. Brock Reeve is both the chairman of Medisun medical group and National Investment (01227.HK) and a close friend of Mr. Danny Wong during his stay in the United States.They share the same confidence and enthusiasm for stem cell and regenerative medicine.

P2:

Hong Kong Chief Executive Liang Zhen ying visited the Harvard University Stem Cell Institute and exchanged views with the Executive Director, Mr. Brock Reeve, on the development of the stem cell and regenerative medicine industries.

Source: http://www.medisun.hk/

Brock Reeve is the younger brother of the famous American actor Christopher Reeve. Christopher Reeve (September 25, 1952 – October 10, 2004), a New Yorker, famous movie actor, film director, writer, was play in Superman (Kal-El/Clark Kent). He graduated from Cornell University in 1974 with a Bachelor of Arts degree and then entered the Juilliard School in New York. He is also a good friend with another famous actor Robin Williams. In 1978, he starred in the sci-fi film “Superman” for the first time and became a hit. In 1995, an accident occurred during an equestrian competition. The spine was seriously injured and his body was paralyzed. Since then, he has devoted himself to social welfare undertakings and to promote stem cell research. He often holds tour lectures. On October 9, 2004, he died for the myocardial infarction at the age of 52.

Medisun Medical Group 2015-01-26,

Taking the first year of China’s medical reform in 2015 as an opportunity, Mayo and Medisun have joined forces to enter the Chinese medical market in large numbers. It can be said that it is at the right time. Dr. Cao Shengyu, President of Medici Medical Group, former General Manager of Hong Kong Queen Elizabeth Hospital and General Manager of Kowloon China Network and managing the five public hospitals, said: “Based on our experience in investing in hospitals in Hong Kong and China over the past 20 years, and in the new environment of China’s medical system reform, Medisun is confident to introduce Mayo’s advanced medical service system to China and benefit patients. According to the GATT and the planning process of a number of specific work agreements, we will gradually provide Mayo’s medical services from Hong Kong to Beijing and Shanghai.

The establishment of the Mayo affiliated hospital system have truly brought Mayo’s world-class medical care to Chinese patients. Dr. Cao was the President of the China Hospital Society HCA (Hospital Corporation of America), responsible for establishing sino-American joint venture hospital in China.

On January 22, 2015, at the strategic cooperation ceremony between Mayo and Medisun, Mayo President Jeffrey Burton led the Mayo executives to accept the Chinese Song Dynasty Tiansheng Acupuncture Copper Man presented by Chairman Madison

Dr. Zhang Yuanxin, senior vice president of Medisun Medical Group and senior bio-industry analyst on Wall Street in the United States, joined Medisun in recognition of Medisun’s expectations for regenerative medicine and China’s healthcare reform. He said, “The cooperation between Mayo and Medisun began with Medisun’s investment in cutting-edge technologies in regenerative medicine.

The two sides have reached a high consensus on the concept of developing medical services in China. Mayo values Medisun’s strategic position in connecting Hong Kong and connecting things. And Medisun’s existing advanced medical facilities and experienced management team, and reached a long-term cooperation agreement with Medisun. This understanding and understanding laid a solid foundation for the cooperation between the two, and the real benefit is the Chinese patients.

Source: http://www.medisun.hk/